Ravi Salgia, MD, PhD
The testing and identification of biomarkers across the oncology space has transformed therapeutic approaches and sequencing for patients, and the field of non–small cell lung cancer (NSCLC) is no exception. In fact, it has become a standard routine in clinical practice.
on Advanced Non–Small Cell Lung Cancer, Salgia spoke on the evolution and current state of biomarker testing in the field of NSCLC.
OncLive: Please provide an overview of your lecture on biomarkers in NSCLC.
As you know, lung cancer can be subdivided into histologic subtypes, such as NSCLC and small cell lung cancer. There are also adenocarcinomas, nonsquamous cell carcinomas, squamous cell carcinomas, and sometimes large cell carcinomas. Now, there are subsets in terms of molecular markers, so you can have EGFR
translocations, or ROS1 translocations. I discussed what it means to have those kinds of disorders but, at the same time, how do you detect them? What do you do after patients build resistance to therapy?
How would you categorize the importance of molecular testing?
It is really the standard of care—just like how, for any patient, we do liver and kidney function tests and look at the sodium and potassium [levels]. Looking at the molecular test is the standard of care.
What are your thoughts on next-generation sequencing and the wave of liquid biopsies?
Next-generation sequencing can detect mutations, as well as translocations and amplifications, so you can really accomplish a lot. As you know, the FDA just approved one of the tests, as well. What is important is that this is in the tumor tissue.
... to read the full story